Cat. No.
MABL-3693
Application
IP, modulate, WB, Block, ELISA, FC, IHC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
IDEC-114 (Galiximab)
From
Recombinant Antibody
Specificity
Galiximab is a primatized mAb which consists of human constant and primate (cynomolgus macaque) variable regions and binds specifically to CD80. CD80 is a surface glycoprotein and a member of the B7 family of costimulatory molecules. CD80 antigen regulates T cell activation (through interacting with CD28 or CD152) and is expressed transiently in antigen-presenting cells, T cells and normal B cells, and expressed consitutively on various subtypes of B-cell lymphomas.
Alternative Names
B7-1; T-lymphocyte activation antigen CD80; Activation B7-1 antigen; BB1; CTLA-4 counter-receptor B7.1; B7
UniProt
P33681
Immunogen
Galiximab was prepared by immunizing cynomolgus monkeys with recombinant CD80 antigen. The variable regions of the light and heavy chains were then cloned by being incorporated into a cassette vector (N5LG1) containing human constant region genes and subsequently transfected into the Dg44 CHO cell line (Hariharan K, 2013)
Application Notes
Galiximab acts to decrease in cell proliferation, inhibition of the constitutively active NF-κB pathway, increase in apoptosis and ADCC against various B-cell lymphoma cell lines. Galiximb affects CD28 and CD152 interactions with CD80. This antibody can also be used for FC, WB, ELISA, IP and IHC.
Antibody First Published
Vinjamaram et al. The use of galiximab in non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2008 Oct;8(5):277-82 PMID:18854281
Note on publication
Describes clinical studies where B-Cell Lymphomas in NHL patients are targeted with Galiximab.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
